IL278295B2 - SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES - Google Patents

SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES

Info

Publication number
IL278295B2
IL278295B2 IL278295A IL27829520A IL278295B2 IL 278295 B2 IL278295 B2 IL 278295B2 IL 278295 A IL278295 A IL 278295A IL 27829520 A IL27829520 A IL 27829520A IL 278295 B2 IL278295 B2 IL 278295B2
Authority
IL
Israel
Prior art keywords
solution formulation
formulation
solution
antibody
hum13b8
Prior art date
Application number
IL278295A
Other languages
English (en)
Hebrew (he)
Other versions
IL278295B1 (en
IL278295A (https=
Original Assignee
Merck Sharp & Dohme
Merck Sharp ַ& Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50934859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL278295(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme, Merck Sharp ַ& Dohme Llc filed Critical Merck Sharp & Dohme
Publication of IL278295A publication Critical patent/IL278295A/en
Publication of IL278295B1 publication Critical patent/IL278295B1/en
Publication of IL278295B2 publication Critical patent/IL278295B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL278295A 2012-12-13 2013-12-09 SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES IL278295B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261737035P 2012-12-13 2012-12-13
PCT/US2013/073825 WO2014093203A1 (en) 2012-12-13 2013-12-09 SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES

Publications (3)

Publication Number Publication Date
IL278295A IL278295A (https=) 2020-12-31
IL278295B1 IL278295B1 (en) 2023-11-01
IL278295B2 true IL278295B2 (en) 2024-03-01

Family

ID=50934859

Family Applications (3)

Application Number Title Priority Date Filing Date
IL278295A IL278295B2 (en) 2012-12-13 2013-12-09 SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES
IL307581A IL307581A (en) 2012-12-13 2013-12-09 Information on a solution of engineered anti–IL23–P19 antibodies
IL239150A IL239150B (en) 2012-12-13 2015-06-02 Solution formulations of engineered anti-il-23p19 antibodies

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL307581A IL307581A (en) 2012-12-13 2013-12-09 Information on a solution of engineered anti–IL23–P19 antibodies
IL239150A IL239150B (en) 2012-12-13 2015-06-02 Solution formulations of engineered anti-il-23p19 antibodies

Country Status (31)

Country Link
US (3) US12509509B2 (https=)
EP (1) EP2931313B1 (https=)
JP (1) JP6266012B2 (https=)
KR (1) KR102004585B1 (https=)
CN (1) CN104870016B (https=)
AU (1) AU2013359767B2 (https=)
BR (1) BR112015013540B1 (https=)
CA (1) CA2894869C (https=)
CL (1) CL2015001608A1 (https=)
CY (1) CY1121895T1 (https=)
DK (1) DK2931313T3 (https=)
EA (1) EA034616B1 (https=)
ES (1) ES2732861T3 (https=)
HR (1) HRP20191137T1 (https=)
HU (1) HUE045668T2 (https=)
IL (3) IL278295B2 (https=)
LT (1) LT2931313T (https=)
MX (1) MX357936B (https=)
MY (1) MY187921A (https=)
NZ (1) NZ708443A (https=)
PE (1) PE20151524A1 (https=)
PH (1) PH12015501296B1 (https=)
PL (1) PL2931313T3 (https=)
PT (1) PT2931313T (https=)
RS (1) RS59057B1 (https=)
SI (1) SI2931313T1 (https=)
SM (1) SMT201900414T1 (https=)
TR (1) TR201909584T4 (https=)
UA (1) UA117466C2 (https=)
WO (1) WO2014093203A1 (https=)
ZA (1) ZA201504408B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI738632B (zh) 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
WO2018181876A1 (ja) * 2017-03-31 2018-10-04 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 水性製剤及び注射器入り水性製剤、並びに、抗体タンパク脱凝集剤及び抗体タンパク脱凝集方法
CA3092551A1 (en) * 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2020106948A1 (en) 2018-11-21 2020-05-28 Regeneron Pharmaceuticals, Inc. High concentration protein formulation
EP3904382A4 (en) 2018-11-27 2022-07-13 Innovent Biologics (Suzhou) Co., Ltd. ANTI-IL-23P19 ANTIBODIES AND ITS USES
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
US12493019B2 (en) 2019-02-20 2025-12-09 Amgen Inc. Methods of determining protein stability
WO2020212874A1 (en) * 2019-04-15 2020-10-22 Sun Pharma Global Fze Methods for treatment of subjects with psoriatic arthritis
WO2020234834A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
US12577297B2 (en) * 2019-09-09 2026-03-17 Boehringer Ingelheim International Gmbh Anti-IL-23p19 antibody formulations
CA3164996A1 (en) * 2019-12-20 2021-06-14 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 p19 antibodies and methods of use thereof
CA3178853A1 (en) * 2020-05-13 2021-11-18 Wei Cao Formulation comprising anti-il-23p19 antibody, method for preparing same and use thereof
KR20230023663A (ko) 2020-05-21 2023-02-17 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법
AU2024349247A1 (en) * 2023-09-27 2026-04-16 Samsung Bioepis Co., Ltd. Stable liquid formulation of anti-il-23 antibody

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090311253A1 (en) * 2008-06-03 2009-12-17 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
US20110229490A1 (en) * 2008-08-27 2011-09-22 Schering Corporation Lyophilized Formulations of Engineered Anti-IL-23p19 Antibodies

Family Cites Families (210)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401820A (en) 1981-01-23 1983-08-30 Tanabe Seiyaku Co., Ltd. Process for racemizing optically active α-amino acids or a salt thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1989009402A1 (fr) 1988-03-30 1989-10-05 Toray Industries, Inc. PREPARATION LYOPHILISEE CONTENANT UN ANTICORPS DE L'INTERFERON beta ANTIHUMAIN MARQUE PAR UNE ENZYME ET KIT D'ANALYSE ENZYMATIQUE CONTENANT CETTE PREPARATION
WO1989011297A1 (en) 1988-05-27 1989-11-30 Centocor, Inc. Freeze-dried formulation for antibody products
DE69332643T2 (de) 1992-09-16 2003-11-27 The Scripps Research Institute, La Jolla Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialvirus
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DE69609188T2 (de) 1995-09-18 2000-12-21 Intracel Corp., Issaquah Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
EP2921180B1 (en) 1999-02-22 2019-08-14 University of Connecticut Albumin-free factor VIII formulations
EP1942114A3 (en) 1999-03-11 2008-08-27 Schering Corporation Mammalian cytokines; related reagents and methods
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
CA2388562C (en) 1999-09-09 2014-07-22 Schering Corporation Mammalian cytokines; related reagents and methods
AU1097301A (en) 1999-10-22 2001-05-08 Scripps Research Institute, The Humanization of non-human, mammalian antibodies
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
NZ526720A (en) 2000-12-28 2007-11-30 Altus Pharmaceuticals Inc Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies
EP1801123A3 (en) 2000-12-28 2007-11-21 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2451185A1 (en) 2001-06-21 2003-01-03 Altus Biologics, Inc. Spherical protein particles and methods of making and using them
PH12012502440A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
JP5290489B2 (ja) 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
DE10207178A1 (de) 2002-02-19 2003-09-04 Novosom Ag Komponenten für die Herstellung amphoterer Liposomen
PT1946776T (pt) 2002-02-27 2017-03-17 Immunex Corp Composição de tnfr-fc estabilizada compreendendo arginina
AU2003226356A1 (en) 2002-04-12 2003-10-27 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
WO2004019861A2 (en) 2002-08-28 2004-03-11 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
US20040219150A1 (en) 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
RU2358763C2 (ru) 2003-02-10 2009-06-20 Элан Фармасьютикалз, Инк. Композиции иммуноглобулина и способ их получения
BRPI0408247A (pt) 2003-03-10 2006-03-01 Schering Corp usos de antagonistas e agonistas de il-23 e reagentes relacionados
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
KR101424624B1 (ko) 2003-05-14 2014-07-31 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
WO2005035574A1 (ja) 2003-10-09 2005-04-21 Chugai Seiyaku Kabushiki Kaisha IgM高濃度安定化溶液
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
PE20050925A1 (es) 2003-11-10 2005-11-29 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
WO2005063291A1 (ja) 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha 抗体を含有する安定な水性医薬製剤
DK2311873T3 (en) 2004-01-07 2018-11-26 Novartis Vaccines & Diagnostics Inc M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF
RU2390353C2 (ru) 2004-02-12 2010-05-27 Мерк Патент Гмбх Высококонцентрированные жидкие композиции анти-egfr антител
AU2005215527B2 (en) 2004-02-17 2011-04-07 Merck Sharp & Dohme Corp. Methods of modulating IL-23 activity; related reagents
KR20070009637A (ko) 2004-03-24 2007-01-18 피디엘 바이오파르마 인코포레이티드 암 세포 증식을 억제하는 항α5β1 항체의 용도
EP1755673B1 (en) 2004-04-12 2014-07-23 MedImmune, LLC Anti-il-9 antibody formulations and uses thereof
DE602005022871D1 (de) 2004-06-07 2010-09-23 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
BRPI0513959A (pt) 2004-07-30 2008-05-20 Rinat Neuroscience Corp anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20080057070A1 (en) 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
BRPI0606867A2 (pt) 2005-01-28 2009-07-21 Wyeth Corp formulação lìquida; forma de dosagem unitária farmacêutica; kit; recipiente; método para aumentar a estabilidade de um polipeptìdeo de ligação a antìgeno numa formulação; método para preparar uma forma de dosagem unitária farmacêutica; formulação estável; formulação; e produto terapêutico
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
EP1871806A2 (en) 2005-03-08 2008-01-02 Pharmacia & Upjohn Company LLC ANTI-MAdCAM ANTIBODY COMPOSITIONS
WO2006112838A1 (en) 2005-04-18 2006-10-26 Xtl Biopharmaceuticals Ltd. Stabilized anti-hepatitis b (hbv) antibody formulations
ATE505489T1 (de) 2005-04-22 2011-04-15 Lilly Co Eli Tgf-beta-1-spezifische antikörper
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
NZ563580A (en) 2005-06-07 2010-09-30 Esbatech An Alcon Biomedical R Stable and soluble antibodies inhibiting TNFaplha
KR20080019249A (ko) 2005-06-15 2008-03-03 쉐링 코포레이션 안정한 항체 제형
AU2006265002B2 (en) 2005-06-30 2012-09-20 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
WO2007016562A2 (en) 2005-07-29 2007-02-08 Amgen Inc. Formulations that inhibit protein aggregation
WO2007019232A2 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
DE602006015830D1 (de) 2005-08-25 2010-09-09 Lilly Co Eli Anti-il-23-antikörper
EP3190125A1 (en) 2005-08-31 2017-07-12 Merck Sharp & Dohme Corp. Engineered anti-il-23 antibodies
AR057807A1 (es) 2005-09-12 2007-12-19 Novimmune Sa Formulaciones de anticuerpo anti-cd3
AU2006296399B2 (en) 2005-09-30 2011-01-20 Medimmune Limited Interleukin-13 antibody composition
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
SI1971366T1 (sl) 2005-12-29 2014-10-30 Janssen Biotech, Inc. Humana protitelesa anti-il-23, sestavki, postopki in uporabe
CA2638811A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
WO2007110339A1 (en) 2006-03-28 2007-10-04 F. Hoffmann-La Roche Ag Anti-igf-1r human monoclonal antibody formulation
MX2008013508A (es) 2006-04-21 2008-10-31 Novartis Ag Composiciones farmaceuticas de anticuerpos antagonistas anti-cd40.
JP2009534390A (ja) 2006-04-21 2009-09-24 アムジェン インコーポレイテッド 生物医薬品製剤のための緩衝剤
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
EP2081553B1 (en) 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
US7705132B2 (en) 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
WO2008057240A2 (en) 2006-10-27 2008-05-15 Abbott Biotechnology Ltd. Crystalline anti-htnfalpha antibodies
CN101557799B (zh) 2006-12-05 2012-08-22 克鲁塞尔荷兰公司 液体抗狂犬病抗体制剂
CA2671538A1 (en) 2006-12-14 2008-06-26 Leonard G. Presta Engineered anti-tslp antibody
JP5577098B2 (ja) 2006-12-21 2014-08-20 アムジエン・インコーポレーテツド ポリペプチドを含有する安定な緩衝化された製剤
CA2674608A1 (en) 2007-01-09 2008-07-17 Wyeth Anti-il-13 antibody formulations and uses thereof
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
WO2008100562A2 (en) 2007-02-14 2008-08-21 Medical College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
EP2426145B1 (en) 2007-02-23 2017-01-18 Merck Sharp & Dohme Corp. Engineered anti-il-23p19 antibodies
AR065420A1 (es) * 2007-02-23 2009-06-03 Schering Corp Anticuerpos anti-il-23 p19 de ingenieria
CA2681752A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
CA2682292A1 (en) * 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
EP2170390B1 (en) 2007-06-14 2018-11-07 Biogen MA Inc. Natalizumab antibody formulations
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
EP2170268A2 (en) 2007-06-25 2010-04-07 Amgen, Inc. Compositions of specific binding agents to hepatocyte growth factor
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
US20100286038A1 (en) 2007-09-21 2010-11-11 Valentyn Antochshuk Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
EP2205276A4 (en) 2007-09-28 2012-08-15 Janssen Biotech Inc ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
US9308257B2 (en) 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
KR101247418B1 (ko) 2007-12-21 2013-03-25 에프. 호프만-라 로슈 아게 항체 제형
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
UA100255C2 (uk) 2007-12-28 2012-12-10 Біоінвент Інтернешенл Аб Фармацевтична композиція
EP2249801A2 (en) 2008-02-07 2010-11-17 Amgen Inc. Stabilized protein compositions
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
EP3208612B1 (en) 2008-04-09 2019-09-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US8460886B2 (en) 2008-07-04 2013-06-11 Ono Pharmaceutical Co., Ltd. Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human PD-1 antibody on cancers
CN102159204B (zh) * 2008-09-19 2015-04-01 辉瑞公司 稳定的液体抗体制剂
EP2362767B1 (en) 2008-10-29 2017-12-06 Ablynx N.V. Formulations of single domain antigen binding molecules
WO2010062372A2 (en) 2008-11-03 2010-06-03 President And Fellows Of Harvard College Methods for modulating nf-kb using gibberellins
KR20110097772A (ko) 2008-11-17 2011-08-31 제넨테크, 인크. 생리적 조건하에 거대분자의 응집을 감소시키는 방법 및 제제
WO2010062896A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
WO2010069858A1 (en) 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
AR076640A1 (es) 2009-03-06 2011-06-29 Genentech Inc Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura
MX2011009312A (es) 2009-03-06 2012-02-29 Medimmune Llc Formulaciones de anticuerpos humanizados anti-cd19.
EP2230312A1 (en) 2009-03-19 2010-09-22 Helmholtz-Zentrum für Infektionsforschung GmbH Probe compound for detecting and isolating enzymes and means and methods using the same
MX2011011772A (es) 2009-05-04 2012-02-08 Abbott Biotech Ltd Formulaicones estables de anticuerpos humanos anti-tnf-alfa con alta concentracion de proteina.
US9155745B2 (en) 2009-06-16 2015-10-13 Universite De Geneve Bevacizumab formulations with lower aggregation propensity, comprising corticosteroid anti-inflammatory drugs
CA2765220A1 (en) 2009-07-14 2011-01-20 Biogen Idec Ma Inc. Methods for inhibiting yellow color and peroxide formation in a composition
US20120121580A1 (en) 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
WO2011024862A1 (ja) 2009-08-31 2011-03-03 三洋化成工業株式会社 タンパク質水溶液の安定化剤、この安定化剤を含有するタンパク質水溶液及び液体洗剤組成物、並びに、この安定化剤を用いるタンパク質の安定化方法
EP2473531A4 (en) 2009-09-03 2013-05-01 Merck Sharp & Dohme Anti-gitr antibodies
WO2011028962A1 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody coformulations
PH12012500843A1 (en) 2009-11-04 2019-07-10 Merck Sharp & Dohme Engineered anti-tslp antibody
JP6214161B2 (ja) 2009-12-21 2017-10-18 ジェネンテック， インコーポレイテッド 抗体製剤
MX2012007676A (es) 2009-12-29 2012-08-03 Hoffmann La Roche Nueva formulacion de anticuerpo.
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
US8318807B2 (en) 2010-02-03 2012-11-27 Laurus Labs Private Limited Pterostilbene cocrystals
PE20130203A1 (es) 2010-03-17 2013-03-24 Abbott Res Bv Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
KR20130060227A (ko) 2010-05-03 2013-06-07 제넨테크, 인크. 단백질-함유 제제의 점도 감소에 유용한 조성물 및 방법
US8933075B2 (en) 2010-06-17 2015-01-13 Fuzians Biomedicals, Inc. Compounds useful as antiviral agents, compositions, and methods of use
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
FR2962908A1 (fr) 2010-07-20 2012-01-27 Lfb Biotechnologies Formulation d'anticorps anti-cd20
WO2012018538A2 (en) 2010-07-26 2012-02-09 Schering Corporation Bioassays for determining pd-1 modulation
BR112013008366B1 (pt) 2010-10-06 2022-02-08 Regeneron Pharmaceuticals, Inc Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações
US9458240B2 (en) 2010-12-10 2016-10-04 Novartis Pharma Ag Anti-BAFFR antibody formulations
WO2012135035A1 (en) 2011-03-25 2012-10-04 Amgen Inc. Anti - sclerostin antibody crystals and formulations thereof
ES2676205T3 (es) 2011-03-31 2018-07-17 Merck Sharp & Dohme Corp. Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados
CA2832560A1 (en) 2011-04-07 2012-10-18 Glaxosmithkline Llc Formulations with reduced viscosity
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
US9574005B2 (en) 2011-07-19 2017-02-21 Chugai Seiyaku Kabushiki Kaisha Stable Protein-containing preparation containing argininamide or analogous compound thereof
KR102451116B1 (ko) 2011-10-27 2022-10-06 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체
AU2013212587B2 (en) 2012-01-23 2017-07-20 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-Ang2 antibodies
WO2013164837A1 (en) * 2012-03-07 2013-11-07 Cadila Healthcare Limited Pharmaceutical formulations of tnf-alpha antibodies
EP4039275A1 (en) 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
ES2729603T3 (es) 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
ES2604012T3 (es) 2012-07-04 2017-03-02 F. Hoffmann-La Roche Ag Conjugados de antígeno-anticuerpo unidos covalentemente
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
WO2014031718A1 (en) 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
EP2919812A4 (en) 2012-11-19 2016-05-18 Merck Sharp & Dohme Liquid formulations for TNFR: FC fusion proteins
EP2931311A4 (en) 2012-12-13 2016-08-17 Merck Sharp & Dohme LYOPHILIZED BALLULAR PELLETS OF ANTI-IL-23 ANTIBODIES
US9700633B2 (en) 2013-01-28 2017-07-11 Jenkem Technology Co., Ltd., Tianjin Branch Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
EA201591710A1 (ru) 2013-03-13 2016-03-31 Сиэтл Дженетикс, Инк. Композиции, содержащие циклодекстрин и конъюгат антитело-лекарственное средство
JP6720075B2 (ja) 2013-05-31 2020-07-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 癌のための併用療法
BR112016001522B1 (pt) 2013-07-23 2019-10-01 Novaliq Gmbh Composições de anticorpo estabilizado
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
SG11201601763SA (en) 2013-09-20 2016-04-28 Bristol Myers Squibb Co Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
US9782470B2 (en) 2013-10-16 2017-10-10 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
RU2589691C2 (ru) 2014-06-16 2016-07-10 Общество с ограниченной ответственностью "Промоген-МАТ" Стабильная композиция антитела, специфически связывающегося с her2 рецепторами, и способ ее получения
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
CA2955612C (en) 2014-07-18 2022-05-17 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
US20170239351A1 (en) 2014-08-11 2017-08-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
AU2015305754B2 (en) 2014-08-19 2018-10-25 Merck Sharp & Dohme Llc Anti-tigit antibodies
MX2017006320A (es) 2014-11-17 2017-08-10 Genentech Inc Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
EP3237000A1 (en) 2014-12-23 2017-11-01 Pfizer Inc Stable aqueous antibody formulation for anti tnf alpha antibodies
CN107207594B (zh) 2014-12-23 2019-05-07 百时美施贵宝公司 针对tigit的抗体
EP3247408A4 (en) 2015-01-20 2018-08-22 Immunexcite, Inc. Compositions and methods for cancer immunotherapy
AR103726A1 (es) 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
EP3770171A1 (en) 2015-04-03 2021-01-27 XOMA Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
TN2017000440A1 (en) 2015-04-17 2019-04-12 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
WO2016168133A1 (en) 2015-04-17 2016-10-20 Merck Sharp & Dohme Corp. Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
US20160362489A1 (en) 2015-04-28 2016-12-15 Bristol-Myers Squibb Company Treatment of PD-L1-Positive Melanoma Using an Anti-PD-1 Antibody
US10751412B2 (en) 2015-05-29 2020-08-25 Merck Sharp & Dohme Corp. Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
WO2017025498A1 (en) 2015-08-07 2017-02-16 Pieris Pharmaceuticals Gmbh Novel fusion polypeptide specific for lag-3 and pd-1
EP3334757A4 (en) 2015-08-14 2019-04-03 Merck Sharp & Dohme Corp. ANTI-Tigit ANTIBODY
EA201890618A1 (ru) 2015-09-01 2018-10-31 Ферст Вэйв Байо, Инк. Способы и композиции для лечения состояний, ассоциированных с аномальными воспалительными ответами
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
KR20250073532A (ko) 2015-09-02 2025-05-27 이뮤텝 에스.에이.에스. 항-lag-3 항체
EP3349792A1 (en) 2015-09-14 2018-07-25 Compass Therapeutics LLC Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-
US20170097333A1 (en) 2015-09-28 2017-04-06 Merck Sharp & Dohme Corp. Cell based assay to measure the t-cell stimulating capacity of anti-lag3 antibodies and other agents
CA2999079A1 (en) 2015-09-28 2017-04-06 Jiangsu Hengrui Medicine Co., Ltd. Stable anti-pd-1 antibody pharmaceutical preparation and application thereof in medicine
PL3356413T3 (pl) 2015-10-01 2022-04-19 Potenza Therapeutics, Inc. Białka anty-tigit wiążące antygen oraz sposoby ich zastosowania
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
US20190010224A1 (en) 2015-12-22 2019-01-10 Merck Sharp & Dohme Corp. Formulations of engineered anti-il-10 antibodies
US10221242B2 (en) 2016-01-21 2019-03-05 Pfizer Inc. Antibodies specific for epidermal growth factor receptor variant III and their uses
AU2017266298B2 (en) 2016-05-18 2024-01-04 Boehringer Ingelheim International Gmbh Anti PD-1 and anti-LAG3 antibodies for cancer treatment
SI3468586T1 (sl) 2016-06-14 2025-01-31 Xencor, Inc. Bispecifična protitelesa za zaviralce kontrolnih točk
EP3541413A2 (en) 2016-11-21 2019-09-25 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
BR112019018022A2 (pt) 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
JP7402693B2 (ja) 2017-05-02 2023-12-21 メルク・シャープ・アンド・ドーム・エルエルシー 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法
SG11201910134SA (en) 2017-05-02 2019-11-28 Merck Sharp & Dohme Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
CA3074565A1 (en) 2017-09-05 2019-03-14 Merck Sharp & Dohme Corp. Compounds for reducing the viscosity of biological formulations
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090311253A1 (en) * 2008-06-03 2009-12-17 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
US20110229490A1 (en) * 2008-08-27 2011-09-22 Schering Corporation Lyophilized Formulations of Engineered Anti-IL-23p19 Antibodies

Also Published As

Publication number Publication date
AU2013359767B2 (en) 2018-04-05
CN104870016B (zh) 2018-05-08
AU2013359767A1 (en) 2015-07-23
US20240239884A1 (en) 2024-07-18
JP2016505572A (ja) 2016-02-25
CY1121895T1 (el) 2020-10-14
IL239150B (en) 2020-11-30
BR112015013540A2 (pt) 2017-11-14
MX357936B (es) 2018-07-31
UA117466C2 (uk) 2018-08-10
RS59057B1 (sr) 2019-08-30
IL278295B1 (en) 2023-11-01
ES2732861T3 (es) 2019-11-26
ZA201504408B (en) 2017-09-27
EP2931313B1 (en) 2019-05-08
MY187921A (en) 2021-10-28
HUE045668T2 (hu) 2020-01-28
SI2931313T1 (sl) 2019-09-30
CA2894869C (en) 2021-06-15
MX2015007213A (es) 2016-08-03
TR201909584T4 (tr) 2019-07-22
KR102004585B1 (ko) 2019-07-26
KR20150092763A (ko) 2015-08-13
WO2014093203A1 (en) 2014-06-19
BR112015013540A8 (pt) 2018-04-17
CA2894869A1 (en) 2014-06-19
EA034616B1 (ru) 2020-02-27
IL239150A0 (en) 2015-07-30
JP6266012B2 (ja) 2018-01-24
SMT201900414T1 (it) 2019-09-09
US12509509B2 (en) 2025-12-30
CN104870016A (zh) 2015-08-26
IL307581A (en) 2023-12-01
DK2931313T3 (da) 2019-07-15
CL2015001608A1 (es) 2015-10-30
PL2931313T3 (pl) 2019-10-31
NZ708443A (en) 2018-05-25
EP2931313A4 (en) 2016-08-03
PH12015501296A1 (en) 2015-08-24
PT2931313T (pt) 2019-07-10
US20150329632A1 (en) 2015-11-19
LT2931313T (lt) 2019-09-25
HRP20191137T1 (hr) 2019-09-20
EA201591133A1 (ru) 2015-10-30
IL278295A (https=) 2020-12-31
PE20151524A1 (es) 2015-11-06
EP2931313A1 (en) 2015-10-21
HK1215194A1 (en) 2016-08-19
PH12015501296B1 (en) 2015-08-24
BR112015013540B1 (pt) 2021-04-27
US20210188964A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
IL278295B2 (en) SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES
HRP20201428T1 (hr) Stabilizirani pripravci koji sadrže anti-interleukin-6 receptorska (il-6r) antitijela
IL261547A (en) Antibodies to psychedin and their uses
Kersse et al. NOD-like receptors and the innate immune system: coping with danger, damage and death
FI3353210T3 (fi) Tigit-vasta-aineita ja käyttömenetelmiä
RU2016119755A (ru) Стабильные водные составы на основе антител
ES2548214T3 (es) Variantes del factor de crecimiento de fibroblastos 21
AR128541A2 (es) Métodos para modificar el punto isoeléctrico de anticuerpos mediante la sustitución de aminoácidos en la región de determinación de la complementariedad (cdr)
AR108449A1 (es) Composición farmacéutica
AR090272A1 (es) FORMULACION DE ANTICUERPOS Ab
AR126555A2 (es) Anticuerpos de oncostatina m humana y métodos de uso
ECSP17032530A (es) Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
PE20160225A1 (es) Modulacion de la inmunidad tumoral
AR082017A1 (es) Anticuerpos anti-axl (receptor de tirosina quinasas) y metodos de uso
AR115516A2 (es) Formulación de acción prolongada de la hormona estimuladora de los folículos humana, métodos para prepararla y conjugado de dicha hormona
SI2771031T1 (en) Humanized antibodies that recognize alpha-synuclein
HRP20192285T1 (hr) Anti-ox40 protutijela i postupci uporabe
FI3964529T3 (fi) Ei-estäviä PD1-spesifisiä vasta-aineita
JP2016505572A5 (https=)
FI3083694T3 (fi) Kaninisoituja hiiren anti-koira-pd-1 -vasta-aineita
BR112022001492A2 (pt) Anticorpo anti-il17a humanizado e uso do mesmo
BR112015022119A2 (pt) Polipeptídeo, composto conjugado, composição farmacêutica, ácido nucleico, vetor, células hospedeiras procariótica e eucariótica, método de produção de um polipeptídeo, e, método de tratamento
JP2016535020A5 (https=)
BR112015032200A2 (pt) conjugado anticorpo-droga com estabilidade melhorada, método de preparação, composição farmacêutica e uso do mesmo
IL257208A (en) Brachyury-modified immunotherapeutic preparations